Nilotinib and Imatinib Mesylate in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking
some of the enzymes needed for cell growth.
PURPOSE: This phase II trial is studying how well giving nilotinib together with imatinib
mesylate works in treating patients with early chronic phase chronic myelogenous leukemia.